{"id":"generic-lamotrigine","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Rash (including Stevens-Johnson syndrome risk)"},{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Ataxia"},{"rate":"10-20","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Diplopia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.","oneSentence":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:17.906Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive and monotherapy)"},{"name":"Bipolar I disorder maintenance treatment"},{"name":"Lennox-Gastaut syndrome"}]},"trialDetails":[{"nctId":"NCT01995825","phase":"PHASE4","title":"Lamotrigine Bioequivalence","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02821338","phase":"PHASE1","title":"A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2016-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT02707965","phase":"PHASE1","title":"Characterization of Epilepsy Patients BEEP 2b","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-06-08","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT04015687","phase":"PHASE1","title":"A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-07-15","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT02404168","phase":"PHASE4","title":"BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-07-07","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT01733394","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-12-12","conditions":"Epilepsy","enrollment":54},{"nctId":"NCT01713777","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2013-04","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02429596","phase":"PHASE4","title":"A Trial of Generic Substitution of Antiepileptic Drugs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2012-05","conditions":"Epilepsy","enrollment":200},{"nctId":"NCT00913107","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2007-09","conditions":"Trigeminal Neuralgia","enrollment":21}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"COMPLETED SUICIDE"},{"count":5,"reaction":"CARDIO-RESPIRATORY ARREST"},{"count":5,"reaction":"MATERNAL DRUGS AFFECTING FOETUS"},{"count":3,"reaction":"DRUG ABUSE"},{"count":3,"reaction":"DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS"},{"count":3,"reaction":"EXPOSURE VIA INGESTION"},{"count":3,"reaction":"SUICIDAL IDEATION"},{"count":3,"reaction":"TOXIC EPIDERMAL NECROLYSIS"},{"count":3,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":2,"reaction":"ANXIETY"}],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Generic lamotrigine","genericName":"Generic lamotrigine","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive and monotherapy), Bipolar I disorder maintenance treatment, Lennox-Gastaut syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}